Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

SVB Leerink Maintains Market Perform on Pfizer, Raises Price Target to $49

SVB Leerink analyst David Risinger maintains Pfizer (NYSE:PFE) with a Market Perform and raises the price target from $48 to $49.

byBenzinga Newsdesk

November 3, 2022

1 minute read

SVB Leerink analyst David Risinger maintains Pfizer (NYSE:PFE) with a Market Perform and raises the price target from $48 to $49.

Wedbush Downgrades Vera Therapeutics to Neutral, Announces $8 Price Target

By Benzinga Newsdesk

Today, 10:05 AM

Wedbush analyst Laura Chico downgrades Vera Therapeutics (NASDAQ:VERA) from Outperform to Neutral and announces $8 price target.

VERA

Rafael Nadal Makes Shocking Announcement, Skipping The Biggest Tennis Events Of The Summer

By Ryan Huizdos

Today, 10:05 AM

Tennis legend Rafael Nadal stunned the sports world Thursday morning by announcing he will skip Wimbledon and the Toyko Olympics.

MGM

CORRECTION: US Bancorp Q3 Adj. EPS $1.18 Beats $1.17 Estimate

By Benzinga Newsdesk

Today, 10:05 AM

US Bancorp (NYSE:USB) reported quarterly earnings of $1.18 per share which beat the analyst consensus estimate of $1.17 by 0.85 percent. This is a 9.23 percent decrease over earnings of $1.30 per share from the same

USB

Citigroup Upgrades Eli Lilly to Buy, Raises Price Target to $265

By Benzinga Newsdesk

Today, 10:05 AM

Citigroup analyst Andrew Baum upgrades Eli Lilly (NYSE:LLY) from Neutral to Buy and raises the price target from $210 to $265.

LLY

SVB Leerink Maintains Market Perform on Pfizer, Raises Price Target to $49

Related Posts

Wedbush Downgrades Vera Therapeutics to Neutral, Announces $8 Price Target

Rafael Nadal Makes Shocking Announcement, Skipping The Biggest Tennis Events Of The Summer

CORRECTION: US Bancorp Q3 Adj. EPS $1.18 Beats $1.17 Estimate

Citigroup Upgrades Eli Lilly to Buy, Raises Price Target to $265